SB Biologicals

SB Biologicals is a Belgian biotechnology company dedicated to developing next-generation immunotherapies that selectively target the TGF-beta pathway. By focusing on the specific isoforms and activation mechanisms of TGF-beta, the company aims to overcome the toxicity and efficacy limitations of previous pan-TGF-beta inhibitors. Their lead program, SB-001, is a monoclonal antibody designed to block the release of active TGF-beta from specific cellular sources, primarily for the treatment of solid tumors and fibrotic diseases. The company's approach leverages deep expertise in the biology of the tumor microenvironment to restore anti-tumor immune responses. SB Biologicals is a spin-off from the de Duve Institute at UCLouvain and is supported by a consortium of Belgian and international investors.